Logan Coy Related postsA Randomized, Multi-Center, Double-Blinded, Placebo-Controlled Trial of XEMBIFY plus Standard Medical Treatment vs Placebo to Prevent Infections in Hypogammaglobulinemia with CLL, Multiple Myeloma, and Non-Hodgkin LymphomaSeptember 11, 2026A Multicenter, Randomized, Open-label, Phase 2 Study of BMS-986504 Monotherapy in Advanced or Metastatic NSCLC with Homozygous MTAP Deletion After Progression on Prior TherapiesSeptember 11, 2026A Phase 3, Randomized, Double-blind, Add-on Study of Navtemadlin plus Ruxolitinib vs Placebo plus Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis with Suboptimal Response to RuxolitinibSeptember 11, 2026 Previous postA Phase 2, Randomized, Open-label Study of Momelotinib in Participants with Anemia due to Low-risk Myelodysplastic SyndromeNext postA Phase 3, Randomized, Double-blind, Add-on Study of Navtemadlin plus Ruxolitinib vs Placebo plus Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis with Suboptimal Response to Ruxolitinib